Atea Pharma Reports Encouraging Results From Study of Covid-19 Treatment
June 30 2021 - 6:50AM
Dow Jones News
By Chris Wack
Atea Pharmaceuticals Inc. reported positive interim results from
the global Phase 2 study evaluating AT-527 in hospitalized patients
with mild-to-moderate Covid-19.
Roche Holding AG and Atea are jointly developing AT-527, an oral
direct-acting antiviral agent derived from Atea's purine nucleotide
prodrug platform.
The biopharmaceutical company said the interim analysis of the
Phase 2 study included data from 70 hospitalized, high-risk
patients with Covid-19, of which data from 62 patients were
evaluable for virology analysis.
Interim virology results indicated that AT-527 rapidly reduced
viral load levels. At Day 2, patients receiving AT-527 experienced
an 80% greater mean reduction from baseline viral load as compared
with placebo. A sustained difference in viral load reduction was
maintained through Day 8, the company said.
By Day 14, the last viral sampling study day, 47% of patients in
the AT-527 arm and 22% in the placebo arm had no detectable RNA
virus. Nasopharyngeal swabs were measured in a reverse
transcription polymerase chain reaction test for the quantitative
detection of nucleic acid from SARS-CoV-2, the company said.
Consistent with previous studies, AT-527 was generally safe and
well tolerated, the company said.
In this study, there were no drug-related serious adverse
events. Nonserious adverse events were equally distributed across
treatment arms. Most were mild-to-moderate in severity and assessed
as not related to the study drug. No safety concerns or newly
determined risks were identified, the company said.
Atea shares were up 5% to $25.43 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 30, 2021 07:37 ET (11:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024